CTDHoldings 24st Centry Investments Cydodextrins
  • Home
  • Company Info
    • Overview
    • Management Team
    • Board of Directors
    • Mission & Vision
  • Cyclodextrins
    • Trappsol® Cyclo™
    • Trappsol®
    • Aquaplex®
    • Applications
  • Subsidiaries
    • CTD, Inc.
  • Our Business
    • Cyclodextrin Market
  • Media Center
    • Company News
    • Selected Articles
  • Investors
    • News / Events
      • Company News
      • In The News
      • Selected Articles
      • Presentations
      • Email Alerts
    • Company Information
      • Profile
      • Management Team
      • IR Contacts
      • FAQ
    • Financial Information
      • Financials
    • Stock Information
      • Quote
      • Charts
      • Historical Quotes
    • SEC Filings
      • All SEC Filings
      • Insiders
    • Corporate Governance
      • Board of Directors
      • Governance Documents
  • Contact Us
 

Company News

  • Home
  • Investors
  • News / Events
  • Company News
  • All News
  • By Year:
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • CTD Holdings Scientific Advisory Board Endorses Alzheimer’s Disease as Next Indication for Company’s Trappsol® Cyclo™ Drug Development Program
    Jul 18, 2019, 10:24 AM EDT
  • CTD Obtains Right of Reference to Alzheimer’s Disease Expanded Access Data
    Jul 11, 2019, 11:05 AM EDT
  • CTD Appoints Head of Global Regulatory Affairs
    Jul 8, 2019, 8:00 AM EDT
  • CTD Holdings Submits Application for Listing on NASDAQ
    Jun 12, 2019, 12:53 PM EDT
  • CTD Announces Continuation of Expanded Access Program in Single Alzheimer's Patient
    Jun 10, 2019, 8:00 AM EDT
  • CTD Holdings Closes $7.4 Million Private Placement
    May 31, 2019, 12:35 PM EDT
  • CTD Holdings Announces $7.2 Million Private Placement
    May 30, 2019, 9:20 AM EDT
  • CTD Announces Home-Based Dosing of First Patient in US Extension Protocol of Clinical Trial using Intravenous Administration of Trappsol (R) Cyclo (TM) for Niemann-Pick Disease Type C
    May 23, 2019, 8:00 AM EDT
  • CTD Announces Participation and Support for Upcoming Gathering of Patient-Support Organizations for Niemann-Pick Disease type C
    May 16, 2019, 8:00 AM EDT
  • CTD Announces New Expanded Access Program in the United Kingdom using Trappsol(R) Cyclo(TM) Intravenously for Niemann-Pick Disease type C
    May 10, 2019, 8:25 AM EDT
RSS
  • << Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...20
  • Next >>
Show All
  • News / Events
    • Company News
    • In The News
    • Selected Articles
    • Presentations
    • Email Alerts
  • Company Information
  • Financial Information
  • Stock Information
  • SEC Filings
  • Corporate Governance

Links

  • Home
  • Cyclodex
  • Disclaimer
  • Privacy Policy
  • Terms & Conditions
  • Sitemap
  • Contact Us

Investor Quicklinks

  • image description
    IR Overview
  • image description
    IR Contacts
  • image description
    IR FAQ
  • image description
    News/Events
  • image description
    Financial Info
  • image description
    SEC Filing
  • image description
    Corporate Governance
  • image description
    Stock Info

Connect With Us

  • rss
  • youtube
  • mail
© Copyright 2021 Cyclo Therapeutics, Inc. All Rights Reserved. Website by Equisolve